InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,268.80
(
-0.72%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.98
(
0.34%
)
Bitcoin
65,056.42
(
0.14%
)
Post# of 252271
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119879
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 135276

Thursday, 06/28/2012 3:07:21 PM

Thursday, June 28, 2012 3:07:21 PM

Post# of 252271
FDA grants priority review for Bayer's Regorafenib in CRC:

http://finance.yahoo.com/news/u-fda-grants-priority-review-063000304.html

This PR doesn’t disclose the exact PDUFA date, but we now know it’s in late October insofar as the PR states that the submission was made in late April. (Bayer did not disclose the submission until 5/23/12—see #msg-75907495.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up